Galaxy Medicare IPO is scheduled to open on September 10, 2025, and will close on September 12, 2025. This Book Built Issue IPO aims to raise approximately ₹22.31 crores, which includes a fresh issue of ₹17.86 crores and an Offer for Sale (OFS) of up to 8,24,000 equity shares with a face value of ₹10 per share.
The IPO price band is set at ₹51 to ₹54 per share. The allocation is divided among retail investors (35%), Qualified Institutional Buyers (QIBs – 50%), and High Net-worth Individuals (HNIs – 15%). The allotment date for the IPO is September 15, 2025, and the listing on NSE is scheduled for September 17, 2025.
Galaxy Medicare IPO Financial Performance:
- Revenue: ₹36.94 crores in FY2024, up from ₹32.03 crores in FY2023.
- Profit: ₹3.71 crores in FY2024, compared to ₹1.57 crores in FY2023.
Galaxy Medicare IPO Date & Price Band Details
Galaxy Medicare IPO opens on September 10, 2025, and closes on September 12, 2025. This Book Built Issue has a face value of ₹10 and a price band of ₹51-54 per share, raising ₹22.31 crores with a fresh issue of ₹17.86 crores and OFS of 8,24,000 shares, listing on NSE SME.
| Category | Details |
|---|---|
| IPO Open Date | September 10, 2025 |
| IPO Close Date | September 12, 2025 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹51 to ₹54 Per Share |
| Issue Size | Approx ₹22.31 Crores |
| Fresh Issue | Approx ₹17.86 Crores |
| Offer for Sale | Approx 8,24,000 Equity Shares |
| Lot Size | 2,000 Shares |
| Issue Type | Book Built Issue |
| IPO Listing | NSE SME |
| DRHP Draft Prospectus | Click Here |
| RHP Draft Prospectus | Click Here |
Galaxy Medicare IPO Market Lot
Galaxy Medicare IPO Application Details: The retail investors can apply for a minimum and maximum of 2 lots (4,000 shares) worth ₹2,16,000. S-HNI investors can apply 3 to 9 lots (6,000–18,000 shares), and B-HNI investors can apply a minimum of 10 lots (20,000 shares) worth ₹10,80,000.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 4,000 | ₹2,16,000 |
| Retail Maximum | 2 | 4,000 | ₹2,16,000 |
| S-HNI Minimum | 3 | 6,000 | ₹3,24,000 |
| S-HNI Maximum | 9 | 18,000 | ₹9,72,000 |
| B-HNI Minimum | 10 | 20,000 | ₹10,80,000 |
The Galaxy Medicare IPO Subscription Status will be updated after the bidding process begins on September 10, 2025.
Galaxy Medicare IPO Reservation
Galaxy Medicare IPO Reservation: The IPO allocation is divided among investors with QIBs receiving 50%, NIIs allocated 15%, and retail investors getting 35% of the net offer, ensuring a balanced opportunity for all investor categories in this Book Built Issue.
| Investor Category | Share Offered |
|---|---|
| QIB Shares Offered | 50% of the Net Offer |
| NII Shares Offered | 15% of the Net Offer |
| Retail Shares Offered | 35% of the Net Offer |
Galaxy Medicare IPO Anchor Investors
Galaxy Medicare IPO Anchor Investors: The anchor bidding date is set for September 2025, with the anchor investors list available in PDF. The lock-in period for 50% of shares ends in 30 days (October 2025), and the remaining 50% ends in 90 days (December 2025), ensuring stability before public listing.
| Type | Details |
|---|---|
| Anchor Bidding Date | September, 2025 |
| Anchor Investors List | Click Here |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| lock-in period end date 50% shares (30 Days) | October, 2025 |
| lock-in period end date 50% shares (90 Days) | December, 2025 |
Galaxy Medicare IPO Allotment & Listing Dates
Galaxy Medicare IPO Key Dates: The IPO opens on September 10, 2025, and closes on September 12, 2025 with a bidding cut-off at 5 PM. Basis of allotment will be finalized on September 15, 2025, with refunds and credit to Demat accounts on September 16, 2025. The IPO will list on NSE on September 17, 2025.
| Type | Date |
|---|---|
| IPO Open Date: | September 10, 2025 |
| IPO Close Date: | September 12, 2025 |
| Basis of Allotment: | September 15, 2025 |
| Refunds: | September 16, 2025 |
| Credit to Demat Account: | September 16, 2025 |
| IPO Listing Date: | September 17, 2025 |
| IPO Bidding Cut-off Time: | September 12, 2025 – 5 PM |
Galaxy Medicare IPO: Promoters and Holding Pattern
Galaxy Medicare IPO Promoters & Holding Pattern: The company is promoted by Abhiraj Singh Bhal, Raghav Chandra, and Varun Khaitan. Pre-IPO promoter holding stands at 1,18,63,983 shares (89.49%), which will reduce to 1,51,71,983 shares (64.60%) post-IPO, reflecting the equity dilution after the public issue.
| Particular | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 1,18,63,983 | 89.49% |
| Promoter Holding Post Issue | 1,51,71,983 | 64.60% |
Objects of the Issue & Utilisation of proceeds – Galaxy Medicare IPO
Galaxy Medicare IPO – Objects of the Issue & Utilisation of Proceeds: The IPO proceeds will be utilized for funding capital expenditure for new machinery at the Bhubaneshwar facility, working capital requirements, and general corporate purposes. A portion will also cover offer-related expenses, ensuring business expansion and operational efficiency.
| Purpose | Crores | Change% |
|---|---|---|
| Funding Capital Expenditure requirement towards purchase of machinery for the existing manufacturing facility at Bhubaneshwar, Odisha | 48.88 | -% |
| Funding the working capital requirements | 99.78 | -% |
| General Corporate Purposes | – | -% |
| To meet the offer related expenses | – | -% |
Galaxy Medicare IPO Company Financial Report
Galaxy Medicare Financials: The company has shown consistent revenue and profit growth with revenue rising from ₹30.74 crore in 2023 to ₹36.94 crore in 2024 and PAT increasing from ₹0.21 crore to ₹3.71 crore. Assets remain stable, reflecting strong financial health, making it a promising IPO investment opportunity.
| Period Ended | Revenue | Expense | PAT | Assets |
|---|---|---|---|---|
| 2023 | ₹30.74 | ₹29.29 | ₹0.21 | ₹30.46 |
| 2023 | ₹32.03 | ₹30.99 | ₹1.57 | ₹32.31 |
| 2024 | ₹36.94 | ₹32.62 | ₹3.71 | ₹32.53 |
| 2025 | ₹17.78 | ₹15.36 | ₹1.71 | ₹31.90 |
Galaxy Medicare IPO Valuation – FY2024
Galaxy Medicare Key Financial Metrics: The company demonstrates strong financial performance with ROE of 23.85%, ROCE at 23.80%, EBITDA margin of 16.91%, and PAT margin of 10.26%. Debt-to-equity ratio stands at 0.52, EPS is ₹3.14, and NAV is ₹13.10, reflecting a solid IPO investment potential.
| KPI | Values |
|---|---|
| ROE: | 23.85% |
| ROCE: | 23.80% |
| EBITDA Margin: | 16.91% |
| PAT Margin: | 10.26% |
| Debt to equity ratio: | 0.52 |
| Earning Per Share (EPS): | ₹3.14 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 23.85% |
| Net Asset Value (NAV): | ₹13.10 |
Galaxy Medicare IPO Peer Group Comparison
Galaxy Medicare Peer Comparison: Compared to peers, Galaxy Medicare shows stronger profitability and financial metrics. While Adeshwar Meditex has an EPS of 1.39 and RoNW 2.52%, and KMS Medisurgi reports EPS 1.38 and RoNW 1.02%, Galaxy Medicare demonstrates higher earnings, robust RoNW, and better NAV, making it a promising IPO investment.
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Adeshwar Meditex Limited | 1.39 | 17.27 | 2.52% | 24.82 | 0.90 Cr. |
| KMS Medisurgi Limited | 1.38 | 90.58 | 1.02% | 23.41 | 0.08 Cr. |
Galaxy Medicare Company Overview, Review, Key Points, Strengths, and Risks
Galaxy Medicare Limited is an Indian manufacturer, trader, and exporter of medical devices and surgical products, including Plaster of Paris (POP) bandages, surgical dressings, and other consumables. Founded in 1992, the company is headquartered in Bhubaneswar, Odisha. It is an ISO 9001:2015 and ISO 13485:2016 certified company, with a focus on manufacturing and supplying a wide range of products for wound care and orthopedic needs.
The company has a diversified business model that includes:
- In-house manufacturing: Producing its own line of products under registered trademarks like POP BAND, POP CAST, and CARETAPE.
- Contract manufacturing (OEM): Manufacturing products for other companies.
- Institutional and government sales: Supplying to central and state health departments, as well as corporate hospitals.
- Exports: Expanding its presence in international markets such as Bangladesh and Nepal.
- Trading: Engaging in the trading of medical devices and other surgical dressings.
Financial Performance (as of FY2025)
- Total Income: ₹40.27 crore
- Profit After Tax (PAT): ₹3.37 crore
- Revenue Growth: 9% from the previous financial year.
- PAT Change: A 9% drop from the previous financial year.
Key Points
- Focus on Surgical Consumables: The company specializes in products like bandages, surgical tapes, wound dressings, and orthopedic items.
- Established Brand & Reputation: With over three decades in the industry, Galaxy Medicare has built a reputation as a reliable manufacturer and supplier, both domestically and internationally.
- Diversified Revenue Streams: The multi-faceted business model, including manufacturing, trading, and exports, helps to mitigate risks and provides multiple avenues for growth.
- ISO Certified: The company holds ISO 9001:2015 and ISO 13485:2016 certifications, demonstrating its commitment to quality management systems for medical devices.
- IPO: As of September 2025, Galaxy Medicare is in the process of an Initial Public Offering (IPO) to raise capital for expanding its manufacturing capabilities and funding working capital requirements.
Strengths
- Experienced Management: The company is led by an experienced team, with its founder, Mr. Dillip Kumar Das, as the Managing Director.
- Quality and Certifications: The company’s ISO certifications and focus on using premium-grade raw materials help it maintain international quality standards.
- Strong Customer Relationships: Galaxy Medicare has established a strong network of hospitals, clinics, and medical practitioners across India.
- Diversified Portfolio: The wide range of products under 27 registered trademarks, along with different business verticals, provides a stable foundation.
- Export Potential: The company’s established export business, particularly in neighboring countries, offers a path for future international growth.
Risks
- Market Competition: The medical devices and consumables market is competitive, with both domestic and international players.
- Dependence on Healthcare Sector: The company’s performance is closely tied to the health and growth of the healthcare industry, including government spending on healthcare.
- Regulatory Environment: The company is subject to various regulations and compliance requirements for medical device manufacturing and sales. Changes in these regulations could impact its operations.
- Operational Risks: As with any manufacturing company, there are risks associated with supply chain disruptions, fluctuations in raw material costs, and maintaining production efficiency.
- Financial Performance: While the company has shown revenue growth, the recent dip in profit after tax (PAT) may signal potential challenges in cost management or pricing pressures.
Galaxy Medicare IPO Registrar
Cameo Corporate Services Ltd.
Phone: +91-44-28460390
Email: investor@cameoindia.com
Website: https://ipo.cameoindia.com/
IPO Lead Managers aka Merchant Bankers
- Affinity Global Capital Market Pvt.Ltd.
Galaxy Medicare Company Address
Galaxy Medicare Ltd.
Plot No-2, Zone D,
Phase A, Mancheswar Industrial Estate
Khurda
Bhubaneshwar, Odisha, 751010
Phone: +91 9937000991
Email: CS@galaxymed.co.in
Website: http://www.galaxy.in/
FAQs about Galaxy Medicare IPO
Galaxy Medicare Ltd. is an Indian company that manufactures, trades, and exports medical devices and surgical products, including Plaster of Paris bandages, surgical dressings, and other wound care products.
The IPO price band is set at ₹51 to ₹54 per share.
A retail investor needs to apply for a minimum of 2 lots, which totals 4,000 shares, requiring a minimum investment of ₹2,16,000 at the upper price band.
The IPO opens on September 10, 2025, and closes on September 12, 2025.
The lot size is 2,000 shares.
The total issue size is approximately ₹22.31 crore.
The shares will be listed on the NSE SME platform.
The promoters are Abhiraj Singh Bhal, Raghav Chandra, and Varun Khaitan. Please note there is a discrepancy in the provided information. The company’s overview mentions Mr. Dillip Kumar Das as the founder and Managing Director, while the promoter section lists different names. Based on the most common information available for this specific company, the promoters are Mr. Dillip Kumar Das, Mr. Subhasish Das, and Mr. Kiran Das. The provided text appears to have conflicting information.
The net proceeds from the IPO will be used for funding capital expenditure for new machinery at the existing manufacturing facility, meeting working capital requirements, and for general corporate purposes.
The registrar for the IPO is Cameo Corporate Services Ltd.
Disclaimer: This content is provided strictly for educational and informational purposes only. The securities or investments mentioned are based on publicly available information and should not be construed as investment advice or recommendations. Investors are advised to consult with their financial advisor before making any investment decisions.
